Cargando…
Clinical Trial Diversity in Oncology: FDA Takes Action with Post–Marketing Requirements or Commitments
In recent years, there has been a renewed focus on promoting the inclusion of patients from racial and ethnic minority groups in oncology clinical trials. FDA Oncology has long pointed to the underrepresentation of racial minorities in registration trials leading to approval. US FDA’s Guidance on di...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732216/ https://www.ncbi.nlm.nih.gov/pubmed/36318222 http://dx.doi.org/10.1093/oncolo/oyac228 |